Walleye Capital LLC Invests $3.80 Million in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Walleye Capital LLC invested approximately $3.80 million in Xeris Biopharma Holdings, acquiring 691,719 shares, which represents about 0.44% of the company.
• Xeris Biopharma's stock price has recently opened at $7.95, experiencing a 2.3% increase amid various institutional investments.
• The company reported earnings of ($0.01) per share, surpassing analysts' expectations, with revenue of $67.71 million during the last quarter.

Walleye Capital LLC acquired a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 691,719 shares of the company's stock, valued at approximately $3,798,000. Walleye Capital LLC owned about 0.44% of Xeris Biopharma as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. NewEdge Advisors LLC acquired a new position in Xeris Biopharma during the fourth quarter worth $34,000. Raymond James Financial Inc. acquired a new position in Xeris Biopharma during the 4th quarter worth about $45,000. Two Sigma Advisers LP acquired a new position in Xeris Biopharma during the 4th quarter worth about $47,000. Aquatic Capital Management LLC acquired a new position in Xeris Biopharma during the 4th quarter worth about $50,000. Finally, Apella Capital LLC acquired a new position in Xeris Biopharma during the 1st quarter worth about $55,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Stock Up 2.3%

Shares of NASDAQ:XERS opened at $7.95 on Wednesday. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $2.48 and a fifty-two week high of $8.02. The firm's 50 day moving average price is $5.67 and its 200 day moving average price is $4.91. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -37.86 and a beta of 0.65.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.02. The firm had revenue of $67.71 million during the quarter, compared to analyst estimates of $64.58 million. On average, equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, Director John Johnson sold 107,500 shares of the firm's stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total value of $786,900.00. Following the sale, the director directly owned 833,483 shares in the company, valued at $6,101,095.56. This trade represents a 11.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Dawn Halkuff sold 42,500 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $7.28, for a total value of $309,400.00. Following the completion of the sale, the director owned 115,000 shares in the company, valued at approximately $837,200. This represents a 26.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.56% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on XERS. Oppenheimer increased their price target on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Wall Street Zen raised shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. HC Wainwright initiated coverage on shares of Xeris Biopharma in a report on Tuesday, August 12th. They set a "buy" rating and a $10.00 target price on the stock. Finally, Leerink Partners increased their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Tuesday, August 19th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $7.08.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.